VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2017 | Pembrolizumab in the treatment of head and neck cancer: is there more to the story?

Jean-Pascal Machiels • 8 Sep 2017
ESMO 2017 KEYNOTE-040
Warning: array_filter() expects parameter 1 to be array, bool given in /home/customer/www/vjoncology.com/public_html/wp-content/themes/vj/single.php on line 281

Jean-Pascal Machiels, MD, PhD, from the Cliniques Universitaires Saint-Luc, Brussels, Belgium discusses the KEYNOTE-040 study (NCT02252042), a Phase III clinical trial which assessed the efficacy of pembrolizumab versus standard treatment for recurrent or metastatic head and neck cancer. Dr Machiels explains the results and gives his opinion on why they may not be telling us the whole story. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter